SGLT2 inhibition modulates metabolic, vascular, and inflammatory molecular markers in the kidney in youth with type 1 diabetes
Science Translational Medicine · 2026
DOI: 10.1126/scitranslmed.aee1005 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Science Translational Medicine, 2026. Verfasst von Petter Bjornstad und 47 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Metabolism, Endocrinology and Nutrition and UW Medicine Diabetes Institute, University of Washington, Seattle, WA…. Hauptthemen laut MEDLINE: Biomarkers, Diabetes Mellitus, Type 1, Inflammation, Kidney. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: NIDDK NIH HHS, National Institutes of Health, Breakthrough T1D Canada.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Sodium-glucose cotransporter-2 (SGLT2) inhibitors slow diabetic kidney disease progression, but their intrarenal mechanisms remain incompletely understood, particularly in type 1 diabetes (T1D), where kidney protection has not been definitively established. ATTEMPT (NCT04333823) was a placebo-controlled trial in which 98 youth (ages 12 to 21) with T1D and hyperfiltration were randomized 1:1 to dapagliflozin (5 milligrams) or placebo for 16 weeks. Participants underwent sequential kidney biopsies, multiparametric kidney MRI, and plasma and urine proteomics. The sequential research kidney biopsies were performed on adults 18 years or older at one of three sites (baseline n = 16, follow-up n = 11). Single-cell RNA sequencing of 214,415 cells across 27 biopsies revealed coordinated transcriptional shifts across nephron, vascular, and immune compartments. In the proximal tubule, the primary site of SGLT2 expression, dapagliflozin down-regulated glycolysis, gluconeogenesis, and oxidative stress markers. Endothelial cells showed reduced profibrotic and inflammatory gene expression with increased protective factors. Podocytes demonstrated enhanced cytoskeletal reinforcement and suppressed interferon signaling. These molecular changes paralleled clinical improvements, including attenuation of hyperfiltration, improved glycemic control, and normalization of medullary oxygenation. Trajectory analyses revealed dapagliflozin shifted tubular cells from injury-prone toward healthier phenotypes. Cross-cohort comparison against healthy controls showed that more than 55% of dapagliflozin-responsive genes shifted toward healthy control expression patterns. Urine proteomics mirrored tissue changes with decreased injury markers and increased protective proteins. These convergent molecular mechanisms, metabolic reprogramming, dampened inflammation, and normalized oxygen handling provide hypothesis-generating mechanistic insights into potential kidney-protective mechanisms of SGLT2 inhibitor therapy in youth with T1D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Metabolism, Endocrinology and Nutrition and UW Medicine Diabetes Institute, University of Washington, Seattle, WA 98195, USA.
- Division of Endocrinology, Department of Pediatrics, University of Washington and Center for Clinical and Translational Research at Seattle Children's Research Institute, Seattle, WA 98101, USA.
- Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
- Division of Diabetes and Complications, Novo Nordisk, Lexington, MA 02421, USA.
- Department of Radiology, Center for Advanced Imaging, Endeavor Health, Evanston, IL 60201, USA.
- Department of Integrated Physiology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
ORCID-Profile: Petter Bjornstad, Ye Ji Choi, Pottumarthi V Prasad, Kalie L Tommerdahl, Maninderpal Sethi, Shivani Ramesh, Carissa Birznieks, Antoine Clarke, Jacqueline Curtis, Cheril Clarson, Jairo Arturo Pinzon Cortes, Long Yuan, Jenny E Kanter, Karin E Bornfeldt, Tomas Vaisar, Hiddo J L Heerspink, Ian H de Boer, Jesse A Goodrich, Kelly Street, Katherine R Tuttle, Cathy Smith, Jeffrey B Hodgin, Jennifer A Schaub, Viji Nair, Rajasree Menon, Abhijit S Naik, Phillip J McCown, Fadhl AlAkwaa, Sean Eddy, Edgar Otto, Nan Hee Kim, Robert G Nelson, Victor G Puelles, Laura Pyle, Farid H Mahmud, Matthias Kretzler
Förderung
- NIDDK NIH HHS
- National Institutes of Health
- Breakthrough T1D Canada
Zitieren
APA
Bjornstad, P., Choi, Y. J., Narongkiatikhun, P., Karihaloo, A., Prasad, P. V., Li, L. P., Tommerdahl, K. L., Sethi, M., Ramesh, S., Birznieks, C., Clarke, A., Elia, Y., Curtis, J., Clarson, C., Weissenkampen, D., D'Antonio, M., Pinzon Cortes, J. A., Hampson, H., Yuan, L., …, & Kretzler, M. (2026). SGLT2 inhibition modulates metabolic, vascular, and inflammatory molecular markers in the kidney in youth with type 1 diabetes. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aee1005
Vancouver
Bjornstad P, Choi YJ, Narongkiatikhun P, Karihaloo A, Prasad PV, Li LP, et al. SGLT2 inhibition modulates metabolic, vascular, and inflammatory molecular markers in the kidney in youth with type 1 diabetes. Science Translational Medicine. 2026. doi:10.1126/scitranslmed.aee1005
BibTeX
@article{Bjornstad2026,
author = {Bjornstad, Petter and Choi, Ye Ji and Narongkiatikhun, Phoom and Karihaloo, Anil and Prasad, Pottumarthi V and Li, Lu-Ping and Tommerdahl, Kalie L and Sethi, Maninderpal and Ramesh, Shivani and Birznieks, Carissa and Clarke, Antoine and Elia, Yesmino and Curtis, Jacqueline and Clarson, Cheril and Weissenkampen, Dylan and D'Antonio, Matteo and Pinzon Cortes, Jairo Arturo and Hampson, Hailey and Yuan, Long and van Eeghen, Sarah A and Kanter, Jenny E and Bornfeldt, Karin E and Vaisar, Tomas and Ladd, Patricia and Heerspink, Hiddo J L and de Boer, Ian H and Goodrich, Jesse A and Street, Kelly and Tuttle, Katherine R and Bergmann, Kelly R and Smith, Cathy and Hodgin, Jeffrey B and Schaub, Jennifer A and Nair, Viji and Menon, Rajasree and Naik, Abhijit S and McCown, Phillip J and AlAkwaa, Fadhl and Eddy, Sean and Otto, Edgar and Kim, Nan Hee and Nelson, Robert G and Puelles, Victor G and van Raalte, Daniël H and Cherney, David Z I and Pyle, Laura and Mahmud, Farid H and Kretzler, Matthias},
title = {SGLT2 inhibition modulates metabolic, vascular, and inflammatory molecular markers in the kidney in youth with type 1 diabetes},
journal = {Science Translational Medicine},
year = {2026},
doi = {10.1126/scitranslmed.aee1005}
}
EUVIMED